Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
| ▸ | PRKCB | P05771 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | PRKCH | P24723 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.42 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26120415 | 0.87 | PRKD3 (0.38) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL18623589 | 0.87 | PRKD3 (0.53) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14139586 | 0.85 | PRKD3 (0.52) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL30891797 | 0.82 | PRKD3 (0.42) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL26117826 | 0.82 | CYP3A4 (0.34) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14012981 | 0.81 | PRKD3 (0.62) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14587065 | 0.81 | PRKD3 (0.62) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL26118427 | 0.80 | LPAR1 (0.42) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL4460725 | 0.79 | CYP3A4 (0.33) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL6618667 | 0.78 | HSD17B10 (0.46) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194367-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2023-10-12 | — | — | WO | disclosed |
| EP-4257648-A1 | TWO-PART CURABLE COMPOSITION | Bostik SA (FR) | 2023-10-11 | — | — | EP | disclosed |
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| EP-2464623-A1 | THE RING OPENING OF LACTONES AND LACTAMS | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| WO-2011019789-A1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | LSS, APH1A, OTUB1 | PRKD3 3004/4885PRKCG 2295/4885PRKCB 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.